Michaela KotrovÃ¡

List of Publications by Year
in descending order

28 papers	1,207 citations	687220 13 h-index	552653 26 g-index
60 all docs	60 docs citations	60 times ranked	1999 citing authors

#	Article	IF	Citations
1	Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods. Blood Advances, 2022, 6, 3006-3010.	2.5	13
2	Next-Generation Sequencing Technology to Identify Minimal Residual Disease in Lymphoid Malignancies. Methods in Molecular Biology, 2021, 2185, 95-111.	0.4	6
3	Thymic Hyperplasia with Lymphoepithelial Sialadenitis (LESA)-Like Features: Strong Association with Lymphomas and Non-Myasthenic Autoimmune Diseases. Cancers, 2021, 13, 315.	1.7	7
4	UMIc: A Preprocessing Method for UMI Deduplication and Reads Correction. Frontiers in Genetics, 2021, 12, 660366.	1.1	9
5	Immune Gene Rearrangements: Unique Signatures for Tracing Physiological Lymphocytes and Leukemic Cells. Genes, 2021, 12, 979.	1.0	10
6	Disease Kinetics Measured By Circulating Tumor DNA Correlates with Treatment Response after Tafasitamab in Combination with R-CHOP with or without Lenalidomide in First Line Treatment of DLBCL. Blood, 2021, 138, 3498-3498.	0.6	0
7	NGS-Based MRD Quantitation: An Alternative to qPCR Validated on a Large Consecutive Cohort of Children with ALL. Blood, 2021, 138, 1314-1314.	0.6	2
8	Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia. Leukemia, 2020, 34, 1154-1157.	3.3	12
9	Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. Blood, 2020, 136, 2851-2863.	0.6	47
10	Automation of Amplicon-Based Library Preparation for Next-Generation Sequencing by Centrifugal Microfluidics. Analytical Chemistry, 2020, 92, 12833-12841.	3.2	15
11	Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia, 2019, 33, 2241-2253.	3.3	177
12	Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. Leukemia, 2019, 33, 2254-2265.	3.3	70
13	Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS. Leukemia, 2019, 33, 2227-2240.	3.3	92
14	Association of 17q24.2â€q24.3 deletions with recognizable phenotype and short telomeres. American Journal of Medical Genetics, Part A, 2018, 176, 1438-1442.	0.7	5
15	Nextâ€generation amplicon TRB locus sequencing can overcome limitations of flowâ€cytometric Vβ2 expression analysis and confirms clonality in all Tâ€cell prolymphocytic leukemia cases. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2018, 93, 1118-1124.	1.1	12
16	Monitoring of the Clonal Architecture of B-Cell Precursor ALL during Induction Chemoimmunotherapy. Blood, 2018, 132, 1555-1555.	0.6	0
17	The IG/TR Next Generation Marker Screening Developed within Euroclonality-NGS Consortium Is Successful in 94% of Acute Lymphoblastic Leukemia Samples. Blood, 2018, 132, 2830-2830.	0.6	2
18	ETV6/RUNX1â€like acute lymphoblastic leukemia: A novel Bâ€cell precursor leukemia subtype associated with the CD27/CD44 immunophenotype. Genes Chromosomes and Cancer, 2017, 56, 608-616.	1.5	63

#	Article	IF	Citations
19	Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?. Molecular Diagnosis and Therapy, 2017, 21, 481-492.	1.6	41
20	Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood, 2017, 129, 347-357.	0.6	323
21	Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Blood Advances, 2017, 1, 2456-2466.	2.5	84
22	Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Hematology American Society of Hematology Education Program, 2017, 2017, 13-21.	0.9	59
23	NGS-Based Minimal Residual Disease (MRD) after Stem Cell Transplantation (SCT) Is More Specific for Relapse Prediction Than qPCR and Suggests the Possibility of False-Positive qPCR Results. Blood, 2016, 128, 3494-3494.	0.6	1
24	The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL. Blood, 2015, 126, 1045-1047.	0.6	82
25	Polyclonal, newly derived T cells with low expression of inhibitory molecule PD-1 in tonsils define the phenotype of lymphocytes in children with Periodic Fever, Aphtous Stomatitis, Pharyngitis and Adenitis (PFAPA) syndrome. Molecular Immunology, 2015, 65, 139-147.	1.0	38
26	Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms. Blood, 2015, 126, 1411-1411.	0.6	1
27	The TREC/KREC Assay for the Diagnosis and Monitoring of Patients with DiGeorge Syndrome. PLoS ONE, 2014, 9, e114514.	1.1	34
28	Next Generation Amplicon Sequencing of Immunoglobulin Heavy Chain Gene Rearrangaments for Minimal Residual Disease (MRD) Stratification in Childhood Acute Lymphoblastic Leukemia (ALL): A Comparison with Classical qPCR-Based Technique. Blood, 2014, 124, 2395-2395.	0.6	0